More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$220034800
EPS
-1.23
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
3.558618
Previous close
$1.11
Today's open
$1.09
Day's range
$0.98 - $1.16
52 week range
$0.98 - $4.23
show more
CEO
Steven Nichtberger
Employees
156
Headquarters
Philadelphia, PA
Exchange
Nasdaq Global Select
Shares outstanding
215720392
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Cabaletta Bio: Revisiting A Wrong Call
Cabaletta Bio remains a Buy: its $276 million valuation sits below $299 million in cash, assigning little value to rese-cel. Rese-cel shows encouraging autoimmune responses and tolerability, but CABA's dermatomyositis readout has slipped to late 2027, with a 2028 BLA planned. Cash should fund CABA into Q1 2028, placing the submission near the end of its runway and making further dilution likely.
Seeking Alpha • Nov 16, 2026

Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroids
GlobeNewsWire • Nov 8, 2026

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data
GlobeNewsWire • Nov 5, 2026

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewsWire • Nov 4, 2026

Cabaletta Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference: Meetings with investors and a webcasted fireside chat at 9:00 a.m. ET on Tuesday, November 10, 2026, in Boston, MA.
GlobeNewsWire • Nov 3, 2026

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns
Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase 1/2 data expected mid-2027 and BLA submission planned for late 2027. A recent 10-year manufacturing deal with Cellares lowers future COGS, supporting margin expansion if rese-cel is approved.
Seeking Alpha • Oct 13, 2026

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 14, 2026

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel
GlobeNewsWire • Aug 13, 2026

Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.
Seeking Alpha • Jun 26, 2026

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • Jun 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Cabaletta Bio Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.